COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management

CDC. Cases of Coronavirus Disease (COVID-19) in the U.S., 2020. JHU, COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), 2020. Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Zheng, 2020, SARS-CoV-2: an emerging coronavirus that causes a global threat, Int. J. Biol. Sci., 16, 1678, 10.7150/ijbs.45053 Zhai, 2020, The epidemiology, diagnosis and treatment of COVID-19, Int. J. Antimicrob. Agents, 55, 105955, 10.1016/j.ijantimicag.2020.105955 South, 2020, COVID-19, ACE2, and the cardiovascular consequences, Am. J. Physiol. Heart Circ. Physiol., 318, H1084, 10.1152/ajpheart.00217.2020 Richardson, 2020, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, 323, 2052, 10.1001/jama.2020.6775 Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for disease control and prevention, JAMA, 323, 1239, 10.1001/jama.2020.2648 Long, 2020, Cardiovascular complications in COVID-19, Am. J. Emerg. Med., 10.1016/j.ajem.2020.04.048 Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb. Res., 191, 145, 10.1016/j.thromres.2020.04.013 Sanders, 2020, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA, 323, 1824 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor, Cell, 181, e8 Brufsky, 2020, Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic, J. Med. Virol., 92, 770, 10.1002/jmv.25887 Tikellis, 2012, Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease, Int. J. Pept., 2012, 256294, 10.1155/2012/256294 Kalra, 1981, Differential response to methionine-enkephalin in basal hypothalamus and preoptic area following hypothalamic deafferentation, Brain Res., 215, 410, 10.1016/0006-8993(81)90526-6 Lakkireddy, 2020, Circulation Purohit, 2013, Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation, Circulation, 128, 1748, 10.1161/CIRCULATIONAHA.113.003313 Lippi, 2020, Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19), Ann. Clin. Biochem., 57, 262, 10.1177/0004563220922255 1963, JAMA, 184, 167- Sharma, 2010, Acute respiratory distress syndrome, BMJ Clin. Evid., 2010, 1511 Bansal, 2020, Cardiovascular disease and COVID-19, Diabetes Metab. Syndr., 14, 247, 10.1016/j.dsx.2020.03.013 Ferreira, 2012, Regulation of cardiac excitability by protein kinase C isozymes, Front. Biosci. (Schol. Ed.), 4, 532, 10.2741/s283 Mehta, 2007, Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, Am. J. Physiol. Cell Physiol., 292, C82, 10.1152/ajpcell.00287.2006 Dusi, 1993, Relationship between phosphorylation and translocation to the plasma membrane of p47phox and p67phox and activation of the NADPH oxidase in normal and Ca(2+)-depleted human neutrophils, Biochem. J., 290, 173, 10.1042/bj2900173 Jagu, 2013, Identifying potential functional impact of mutations and polymorphisms: linking heart failure, increased risk of arrhythmias and sudden cardiac death, Front. Physiol., 4, 254, 10.3389/fphys.2013.00254 Spinelli, 2016, Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation, J. Int. Med. Res., 44, 81, 10.1177/0300060515593258 Yuen, 2020, SARS-CoV-2 and COVID-19: The most important research questions, Cell Biosci., 10, 40, 10.1186/s13578-020-00404-4 Yao, 2018, Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation, Circulation, 138, 2227, 10.1161/CIRCULATIONAHA.118.035202 Cizgici, 2020, COVID-19 myopericarditis: it should be kept in mind in today's conditions, Am. J. Emerg. Med., 10.1016/j.ajem.2020.04.080 Hirano, 2020, COVID-19: a new virus, but a familiar receptor and cytokine release syndrome, Immunity, 10.1016/j.immuni.2020.04.003 Ramasamy, 2018, Established and novel pathophysiological mechanisms of pericardial injury and constrictive pericarditis, World J. Cardiol., 10, 87, 10.4330/wjc.v10.i9.87 Montecucco, 2012, Inflammatory cardiovascular risk biomarkers: update on novelties and limitations, Mediators Inflamm., 2012, 515692, 10.1155/2012/515692 Dabbagh, 2020, Basir MB. Cardiac tamponade secondary to COVID-19, JACC Case Rep., 10.1016/j.jaccas.2020.04.009 Hua, 2020, Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19, Eur. Heart J., 10.1093/eurheartj/ehaa253 Liu, 2020, Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?, J. Autoimmun., 102452, 10.1016/j.jaut.2020.102452 Kakihana, 2016, Sepsis-induced myocardial dysfunction: pathophysiology and management, J. Intensive Care, 4, 22, 10.1186/s40560-016-0148-1 S. Hendren Nicholas, H. Drazner Mark, B. Bozkurt, J.L.T. Cooper, Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation.0. Rizzo, 2020, COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?, Basic Res. Cardiol., 115, 31, 10.1007/s00395-020-0791-5 Fung, 2016, Myocarditis, Circ. Res., 118, 496, 10.1161/CIRCRESAHA.115.306573 Anand, 2003, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs, Science, 300, 1763, 10.1126/science.1085658 Bracamonte-Baran, 2017, Cardiac autoimmunity: myocarditis, Adv. Exp. Med. Biol., 1003, 187, 10.1007/978-3-319-57613-8_10 Clerkin, 2020, COVID-19 and cardiovascular disease, Circulation, 141, 1648, 10.1161/CIRCULATIONAHA.120.046941 Minhas, 2020, Takotsubo syndrome in the setting of COVID-19 infection, JACC Case Rep., 10.1016/j.jaccas.2020.04.023 M.F. Konig, M. Powell, V. Staedtke, R.-Y. Bai, D.L. Thomas, N. Fischer, et al., Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome. medRxiv. 2020:2020.04.02.20051565. Komamura, 2014, Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment, World J. Cardiol., 6, 602, 10.4330/wjc.v6.i7.602 I. Basu-Ray, N.K. Almaddah, A. Adeboye, M.P. Soos, Cardiac Manifestations Of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC., 2020. Driggin, 2020, Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic, J. Am. Coll. Cardiol., 75, 2352, 10.1016/j.jacc.2020.03.031 Bangalore, 2020, ST-segment elevation in patients with Covid-19 — a case series, N. Engl. J. Med., 10.1056/NEJMc2009020 Atri, 2020, COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies, JACC Basic Transl. Sci., 10.1016/j.jacbts.2020.04.002 Kang, 2020, Cardiovascular manifestations and treatment considerations in covid-19, Heart, 10.1136/heartjnl-2020-317056 Inciardi, 2020, Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19), JAMA Cardiol., 10.1001/jamacardio.2020.1096 Li, 2020, Cardiac valves: another “Disaster-Hit Area” of COVID-19 patients?, Heart Lung, 10.1016/j.hrtlng.2020.05.004 Hirano, 2020, COVID-19: a new virus, but a familiar receptor and cytokine release syndrome, Immunity, 52, 731, 10.1016/j.immuni.2020.04.003 Dinh, 2014, Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension, Biomed. Res. Int., 2014, 406960, 10.1155/2014/406960 Connors, 2020, Thromboinflammation and the hypercoagulability of COVID-19, J. Thromb. Haemost., 10.1111/jth.14849 Wallez, 2008, Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis, Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids, 1778, 794, 10.1016/j.bbamem.2007.09.003 Bermejo-Martin, 2018, Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease), J. Clin. Med., 7, 10.3390/jcm7110400 Tomar, 2020, Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19, Cells, 9, 10.3390/cells9061383 Bikdeli, 2020, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J. Am. Coll. Cardiol., 10.1016/j.jacc.2020.04.031 Ullah, 2020, COVID-19 complicated by acute pulmonary embolism and right-sided heart failure, JACC Case Rep., 10.1016/j.jaccas.2020.04.008 Wang, 2020, Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19, Lancet Haematol., 7, e362, 10.1016/S2352-3026(20)30109-5 McCreary, 2020, Coronavirus disease 2019 treatment: a review of early and emerging options, Open Forum Infect. Dis., 7, ofaa105, 10.1093/ofid/ofaa105 Quiros Roldan, 2020, The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis?, Pharmacol. Res., 158, 104904, 10.1016/j.phrs.2020.104904 Roden, 2020, Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment, Circulation, 10.1161/CIRCULATIONAHA.120.047521 Borba, 2020, Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a Randomized Clin. Trial, JAMA Netw. Open., 3, e208857-e, 10.1001/jamanetworkopen.2020.8857 Lippi, 2020, Electrolyte imbalances in patients with severe coronavirus disease 2019 COVID-19, Ann. Clin. Biochem., 10.1177/0004563220922255 Kazory, 2020, SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill, Proc. (Bayl. Univ. Med. Cent.), 1 Yang, 1996, Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence, Circulation, 93, 407, 10.1161/01.CIR.93.3.407 Chang, 2020, COVID-19 infection unmasking brugada syndrome, HeartRhythm Case Rep., 6, 237, 10.1016/j.hrcr.2020.03.012 Sorgente, 2020, The known into the unknown: Brugada syndrome and COVID-19, JACC Case Rep., 10.1016/j.jaccas.2020.04.006 Wu, 2020, SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes, Heart Rhythm, 10.1016/j.hrthm.2020.03.024 Bellamy, 2019, Catecholaminergic polymorphic ventricular tachycardia: the cardiac arrest where epinephrine is contraindicated, Pediatr. Crit. Care Med., 20, 262, 10.1097/PCC.0000000000001847 G. Stefanini Giulio, M. Montorfano, D. Trabattoni, D. Andreini, G. Ferrante, M. Ancona, et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation. Mahmud, 2020, Management of acute myocardial infarction during the COVID-19 pandemic, J. Am. Coll. Cardiol., 10.1016/j.jacc.2020.04.039 Zeng, 2020, How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital, Intensive Care Med., 1–3 Zhou, 2020, Antiplatelet therapy after percutaneous coronary intervention in patients with COVID-19: implications from clinical features to pathologic findings, Circulation, 141, 1736, 10.1161/CIRCULATIONAHA.120.046988 ACC. Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure. Cardiology Magazine. ACC: ACC, 2020. Vaduganathan, 2020, Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N. Engl. J. Med., 382, 1653, 10.1056/NEJMsr2005760 Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 2605, 10.1161/CIRCULATIONAHA.104.510461 HFSA/ACC/AHA. Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. ACC News Story2020. Mancia, 2020, Renin-angiotensin-aldosterone system blockers and the risk of Covid-19, N. Engl. J. Med., 10.1056/NEJMoa2006923 Tavazzi, 2020, Myocardial localization of coronavirus in COVID-19 cardiogenic shock, Eur. J. Heart Fail., 10.1002/ejhf.1828 Zeng, 2020, First case of COVID-19 complicated with fulminant myocarditis: a case report and insights, Infection, 10.1007/s15010-020-01424-5 Li, 2020, Prognostic value of right ventricular longitudinal strain in patients with COVID-19, JACC: Cardiovascular Imag., 3423 Hu, 2020, Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin, Eur. Heart J., 10.1093/eurheartj/ehaa190 Mason, 1995, A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators, N. Engl. J. Med., 333, 269, 10.1056/NEJM199508033330501 Chau, 2020, The imperfect cytokine storm: severe COVID-19 with ARDS in patient on durable LVAD support, JACC: Case Rep., 424 Chen, 2013, Corticosteroids for viral myocarditis, Cochrane Database Syst. Rev., Cd004471 Belhamissi, 1982, Pulmonary embolism with massive hepatic cytolysis syndrome. Apropos of a case, Ann. Fr. Anesth. Reanim., 1, 521, 10.1016/S0750-7658(82)80095-6 McNamara Dennis, 2001, Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy, Circulation, 103, 2254, 10.1161/01.CIR.103.18.2254 Shen, 2020, Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783 Castiglione, 2020, Statin therapy in COVID-19 infection, Eur. Heart J. Cardiovasc. Pharmacother., 10.1093/ehjcvp/pvaa042 Tadic, 2020, COVID-19, hypertension and cardiovascular diseases: should we change the therapy?, Pharmacol. Res., 158, 104906, 10.1016/j.phrs.2020.104906 Spyropoulos, 2020, Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19, J. Thromb. Haemost., 10.1111/jth.14929 Atallah, 2020, Anticoagulation in COVID-19, Eur. Heart J. Cardiovasc. Pharmacother., 10.1093/ehjcvp/pvaa036 Bikdeli, 2020, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review, J. Am. Coll. Cardiol., 75, 2950, 10.1016/j.jacc.2020.04.031